Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Prostate-specific Antigen After Anatomic Radical Retropubic Prostatectomy. Patterns Of Recurrence And Cancer Control.

C. Pound, A. Partin, J. Epstein, P. Walsh
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
In a series of 1623 men with a follow-up of 5 +/- 3 years (range 1-13) after anatomic RRP for clinically localized prostate cancer, 17% (276/1623) have shown recurrence. A detectable PSA was the only evidence of recurrence in 7.9%, whereas 2.5% have recurred locally and 5.4% have developed distant metastases. The overall actuarial progression-free rate for these men at 10 years was 68%. Actuarial rates at 10 years were 18% for development of an isolated PSA recurrence, 8% for local recurrence, and 9% for distant recurrence. The actuarial likelihood of a postoperative recurrence increased with increasing clinical stage, Gleason score, preoperative PSA level, and pathologic stage. Although not shown in our previous report, the actuarial rate of recurrence of tumors with a Gleason score of 7 was statistically different from that of tumors of higher Gleason score (8-10). As well, men with preoperative PSA levels of 10.1 to 20 ng/mL experienced recurrence at a significantly lower rate than did men with preoperative PSA levels greater than 20 ng/mL. By using a combination of Gleason score, pathologic stage, and surgical margin status, we demonstrated that the presence of a positive surgical margin did not dramatically affect recurrence in tumors of Gleason scores 2 to 6 with capsular penetration. Surgical margin status was important in high-grade tumors with capsular penetration. In fact, tumors with capsular penetration, Gleason score of at least 7, and a positive surgical margin behaved similarly to tumors with invasion of the seminal vesicles. Preservation of potency did not adversely influence cancer control. The Gleason score, presence or absence of seminal vesicle or lymph node involvement, and the timing of PSA recurrence are all important variables in predicting eventual local versus distant failure associated with an isolated rise in serum PSA. Overall actuarial cause-specific survival at 5 and 10 years was 99% and 93%. Although there was no difference in survival among men grouped by TNM stage or preoperative PSA, advancing histologic grade and pathologic stage did have an effect on actuarial cause-specific survival. Men undergoing RRP for clinically localized prostate cancer showed a 16% actuarial rate of development of metastatic disease at 10 years. This is considerably better than conservative therapy and justifies RRP as the treatment of choice for men with clinically localized disease who are otherwise healthy and have a greater than 10-year life expectancy.
This paper references
10.1002/PROS.2990210521
The TNM classification of prostate cancer
F. Schroeder (1992)
10.1016/S0022-5347(17)38491-4
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
J. Oesterling (1991)
10.1097/00000478-199603000-00004
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up.
J. Epstein (1996)
10.1016/0090-4295(94)90180-5
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
A. Partin (1994)
10.1016/S0022-5347(17)35415-0
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup.
J. Epstein (1993)
10.1002/1097-0142(19920701)70:1+<307::AID-CNCR2820701319>3.0.CO;2-N
Prospective, conservative management of localized prostate cancer
G. Jones (1992)
10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y
Correlation of pathologic findings with progression after radical retropubic prostatectomy
J. Epstein (1993)
10.1016/S0022-5347(17)32394-7
The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
J. Trapasso (1994)
10.1016/S0022-5347(17)40079-6
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
A. Partin (1990)
10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J
Expectant management of localized prostatic cancer
W. Whitmore (1991)
10.1016/S0022-5347(17)32397-2
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
W. J. Catalona (1994)
10.1016/S0022-5347(01)66713-2
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
M. Oefelein (1995)
10.1016/S0022-5347(01)66792-2
Prognostic significance of positive surgical margins in radical prostatectomy specimens.
M. Ohori (1995)
10.1002/PROS.2990040204
Nuclear androgen receptors in the epithelium and stroma of human benign prostatic hypertrophic glands
R. Lahtonen (1983)
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
A. Partin (1993)
10.1016/S0022-5347(17)32399-6
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
H. Zincke (1994)
10.1159/000281849
Cancer of the Prostate: Is There a Need for Aggressive Treatment?
B. Moskovitz (1987)
10.1016/S0022-5347(17)32398-4
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
M. Ohori (1994)
10.1001/JAMA.1992.03480160049033
High 10-year survival rate in patients with early, untreated prostatic cancer.
J. E. Johansson (1992)
10.1056/NEJM199401273300403
Results of conservative management of clinically localized prostate cancer.
G. Chodak (1994)



This paper is referenced by
10.1016/j.rpor.2014.10.001
Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients.
G. Apicella (2015)
10.1016/J.CLGC.2019.03.014
Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
Casandra Hernández Hernández (2019)
10.1097/MNM.0b013e3283636eaf
The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option?
C. Nanni (2013)
10.1093/JNCI/91.20.1733
Prostate-specific antigen testing of older men.
H. Carter (1999)
10.1016/S0090-4295(99)00346-5
Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques.
F. Critz (1999)
10.1016/S0090-4295(99)00328-3
Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.
S. Potter (1999)
10.1007/978-1-60761-259-9_22
Management of Newly Diagnosed Metastatic Disease
C. Cowey (2012)
10.1016/S0022-5347(05)67989-X
Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.
J. E. Fowler (2000)
10.1016/S0037-198X(99)80005-4
Prostate cancer: detection, staging, and treatment of localized disease.
S. Potter (1999)
10.1016/s0022-5347(01)62202-x
Anatomic radical prostatectomy: evolution of the surgical technique.
P. Walsh (1998)
10.1016/j.cpet.2009.06.003
PET Imaging of Prostate Cancer Using Radiolabeled Choline.
M. Beheshti (2009)
10.1016/S1278-3218(02)00151-8
Surveillance clinique et biologique aprs radiothrapie pour cancer de la prostate localis
N. Salem (2002)
10.6000/1927-7229.2018.07.01.2
Evaluation of Concordance between Gleason Scores of Tansrectal Ultrasound Guided Biopsy and Radical Prostatectomy Samples in Prostate Cancer
M. Değer (2018)
10.1016/S0959-8049(09)70026-7
Treatment of local progression following radiotherapy.
Theo M de Reijke (2009)
10.1007/978-3-319-56114-1_17
Adjuvant or salvage radiotherapy in postoperative prostate cancer
U. Selek (2017)
10.1002/cncr.10811
Validation of a biopsy‐based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma
A. Haese* (2002)
10.1016/j.urolonc.2010.08.019
HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
A. Asimakopoulos (2012)
10.1016/S0022-5347(05)68281-X
Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study.
F. Gilliland (1999)
10.1016/j.urolonc.2009.09.012
Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
W. Kim (2011)
10.17532/JHSCI.2011.104
Is there any relationship between PSA and increased peripheral CD4+CD25highFOX3+ Treg in prostate cancer patients?
Y. Akın (2011)
10.1586/14737140.6.11.1639
Evolving treatment paradigms for locally advanced and metastatic prostate cancer
T. Dorff (2006)
10.1097/01.JU.0000132139.40964.75
Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
C. Ramos (2004)
10.1080/03008880310006931
Old and New Research into Micrometastases in Prostate Cancer
P. Øgreid (2003)
10.1016/S0022-5347(05)67813-5
Beyond prostate specific antigen--markers for prostate cancer for the 21st Century.
D. Kadmon (2000)
Guidelines on Prostate Cancer
A. Heidenreich (2013)
10.1159/000020011
Evaluation of DNA Ploidy Combined with a Cytometric Proliferation Index of Imprints from Core Needle Biopsies in Prostate Cancer
G. Ahlgren (1999)
10.1159/000106096
The Use of Body Mass Index to Predict Pathological Stage in Patients with Clinically Localized Prostate Cancer
K. Pummer (2007)
10.1080/003655901753367541
Relatively High Risk of Treatment Failure after Prostatectomy: Tumour Grade, Histopathological Stage and the Preoperative Serum PSA Level are Key Prognosticators
Jens Andersson, Peter Ekman, Lars Egevad, Magnus Hellst (2001)
Reaction Assay for Human Glandular Kallikrein Variant-specific Reverse Transcriptase-Polymerase Chain Detection of Metastatic Prostate Cancer Using a Splice
Kevin M. Slawin (2013)
10.1046/j.1464-410x.2000.00941.x
Treatment options after failure of local curative treatments in prostate cancer: a controversial issue
C. Schulman (2000)
10.1016/j.acuro.2015.07.006
Prediction of biochemical recurrence after radical prostatectomy. New tool for selecting candidates for adjuvant radiation therapy.
F. Herranz-Amo (2016)
10.1002/cncr.21766
Impact of age, benign prostatic hyperplasia, and cancer on prostate‐specific antigen level
R. Punglia (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar